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ABSTRACT

Introduction Research is a critical pillar in national cancer
control planning. However, there is a dearth of evidence
for countries to implement affordable strategies. The WHO
and various Commissions have recommended developing
stakeholder-based needs assessments based on objective
data to generate evidence to inform national and regional
Handling editor Seye Abimbola prioritisation of cancer research needs and goals.
Methodology Bibliometric algorithms (macros) were
► Additional supplemental
developed and validated to assess cancer research outputs
material is published online only. of all 54 African countries over a 12-year period (2009–
To view, please visit the journal
2020). Subanalysis included collaboration patterns, site
online (http://dx.d oi.org/10.
and domain-specific focus of research and understanding
1136/b mjgh-2022-0 09849).
authorship dynamics by both position and sex. Detailed
subanalysis was performed to understand multiple impact
metrics and context relative outputs in comparison with
RS and VV are joint senior
authors.
the disease burden as well as the application of a funding
thesaurus to determine funding resources.
Received 9 June 2022
Results African countries in total published 23 679 cancer
Accepted 29 August 2022
research papers over the 12-year period (2009–2020) with
the fractional African contribution totalling 16 201 papers
and the remaining 7478 from authors from out with the
continent. The total number of papers increased rapidly
with time, with an annual growth rate of 15%. The 49
sub-Saharan African (SSA) countries together published
just 5281 papers, of which South Africa’s contribution
was 2206 (42% of the SSA total, 14% of all Africa) and
Nigeria’s contribution was 997 (19% of the SSA total, 4%
of all Africa). Cancer research accounted for 7.9% of all
African biomedical research outputs (African research
in infectious diseases was 5.1 times than that of cancer
research). Research outputs that are proportionally low
relative to their burden across Africa are paediatric,
cervical, oesophageal and prostate cancer. African
© Author(s) (or their
research mirrored that of Western countries in terms of its
employer(s)) 2022. Re-use
focus on discovery science and pharmaceutical research.
permitted under CC BY.
The percentages of female researchers in Africa were
Published by BMJ.
comparable with those elsewhere, but only in North African
For numbered affiliations see
and some Anglophone countries.
end of article.
Conclusions There is an imbalance in relevant local
research generation on the continent and cancer control
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efforts. The recommendations articulated in our five-
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point plan arising from these data are broadly focused on
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WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Cancer research that is nationally relevant is cru-

cial for improving affordable, equitable outcomes.
The state of African cancer research has been the
subject of narrative discourse but contemporary objective metrics to benchmark country performances
across the continent are not available.

WHAT THIS STUDY ADDS
⇒ This study provides in depth cancer research perfor-

mance metrics across Africa, with a particular focus
on sub-Saharan Africa. A wide range of performance
and output data, including on author sex, enables
deep benchmarking between African countries and
in comparison to other regions around the world.

HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ The African Cancer Research Intelligence provided

by this study should inform both national cancer
control strategies across Africa to support research
and also international policy towards supporting the
building of research capacity and capability.

structural changes, for example, overt inclusion of research
into national cancer control planning and financial, for
example, for countries to spend 10% of a notional 1%
gross domestic expenditure on research and development
on cancer.

BACKGROUND
Africa is a large and diverse continent made up
of 54 countries (online supplemental e-Table
1). While no pattern can adequately reflect
the breadth and diversity of the African continent, there are estimated to be 198 distinct
ethnolinguistic groups.1 There is a clear division in terms of human development index
(HDI). The five North African countries
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Figure 1 Disability adjusted life years compared to overall
life expectancy. DALYs, disability-adjusted life years;
AO, Angola; BI, Burundi; BF, Burkina Faso; CF, Centra
African Republic; DZ, Algeria; EG, Egypt; GM, Gambia;
LY, Libya; MA, Morocco; MU, Mauritius; MW, Malawi; MZ,
Mozambique; RW, Rwand; TN, Tunisia; ZA, South Africa.

(Algeria, Egypt, Libya, Morocco and Tunisia) are quite
comparable in their demographic, economic and sociocultural background. They also share almost the same
cancer risk and cancer protection factors, that is, level of
industrialisation, control of infectious diseases, etc.2 Sub-
Saharan African (SSA) countries, by comparison, are very
diverse, spanning the HDI range from 0.72 for Botswana
and 0.70 for Gabon and South Africa to just 0.35 in
Niger.3 (The index is based on life expectancy, access to
education and standard of living, see HDI—our World
in data.) Of the 28 countries worldwide currently ranked
by World Bank (2022–2023) as low-income economies,
indicating they are the poorest countries in the world,
25 are located in Africa. Despite these development challenges, populations across Africa are rapidly ageing and
non-communicable diseases, especially cancer (figure 1,
online supplemental e-Table 2), are now a major challenge to health systems and economies.4
Context-relevant research is critical to driving more
affordable, equitable and better outcomes through
national cancer control planning across these diverse
national systems in Africa.5 To date, policy research on
African cancer control has been undertaken through a
descriptive, narrative lens focused on care (outcomes)6
and qualitative work around research barriers.7 The literature has also examined new models for comprehensive
cancer care8 and treatment9 but an objective assessment
of the relative strengths and weaknesses of research at
the country level has been absent. In the recent Lancet
Oncology Commission on sub-
Saharan Africa, authors
noted the dearth of evidence-
based polices and data
to help build a new cancer research ecosystem across
the continent, making the point that, ‘prioritisation of
research needs and goals can be accomplished through
stakeholder-
based needs assessments as well as data-
driven evidence’.10
2

METHODS
Deliberative coproduction and need assessment with
stakeholders
The WHO Strategy on Health Policy and Systems
Research entitled ‘Changing Mindsets’12 stressed that
research should be demand driven and not viewed only
as an activity. We undertook a deliberative demand-
driven approach (arising from a recommendation by
African authors working on the 2022 Lancet Oncology
Saharan Africa to develop
Commission Cancer in sub-
better objective insights into the state of cancer research)
to codevelopment and analysis as previously described
by adapting virtual facilitation practices (group meetings via Zoom) using on-line decision workshops.13 The
original concept and analytical design were codeveloped
between authors led by a core African organisation from
the African Organisation for Research and Training in
Cancer (AORTIC) (MM, VV, JT, RS) through six iterative
rounds with all coauthors. An open call to participate in
this was launched in September 2020 with n=42 and n=31
pan-African participants in rounds 1 and 2. The current
version of this manuscript was shared over a 4-month
window (December 2021 to April 2022) to enable active
feedback and all substantive participants and contributors were invited to be coauthors. A final meeting was
undertaken in February 2021 to achieve consensus on
the research recommendations.14
Bibliometric analysis
We identified cancer research papers (articles and
reviews) in the Web of Science (WoS) in February 2021
from 12 years, 2009–2020, by means of a complex search
strategy or filter.15 This was based on several hundred
specialist cancer journals and title words. These were
each selected if 90% of the papers that they individually
identified were marked as relevant to cancer research by
a number of external experts whom we consulted over a
period of over 25 years, although the filter was modified
over time as additional specialist cancer journals were
published and new title words appeared (mainly drugs
and genes). The search included papers in any journal,
including general medical and basic science journals,
provided that they had a title term indicative of cancer
(composed of 323 words and short phrases).16 This filter
was developed through iterative rounds, which involved
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849
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To provide such a context-
specific cancer research
baseline for both national, regional and international
cancer research systems strengthening, our comparative
bibliometric multivariate analysis covers all countries in
Africa but with a special emphasis on sub-Saharan Africa
(the Middle East and North Africa region has already
been the subject of a separate in-depth analysis).11 The
aim was to examine national-level cancer research system
trends, portfolio balance, focus, strengths and opportunities in order to provide underpinning strategic data for
planning African cancer research strategies.

BMJ Global Health
Bethesda, canc (cancer), dis (disease), Eisai (a pharmaceutical company), family, gene, hosp (hospital),
INSERM, etc. We then compared the integer (or whole)
counts of each country’s cancer research outputs in the
12-year period, 2009–2020, with its biomedical research
output, and compared this ratio with the percentage of
its total disease burden (measured in disability-adjusted
life years (DALYs)) that was attributable to cancer in
2015. (This varied greatly and depended on the degree
of development of the country, from 1.2% in Angola to
nearly 9% in Mauritius.)
Research domains, anatomical sites and levels
The African research publications were categorised into
12 research domains, such as genetics, paediatrics and
surgery. These were defined with subfilters that each
contained a set of title words and journal name strings
to categorise relevant papers into particular domains.
We also assigned the papers to some 16 manifestations
of cancer (see table 1) by means of a further macro
based on title words and some journal names (eg, Lung
Cancer, Breast Cancer Research). Some papers were classified into more than one domain or anatomical site, but
others could not be so classified. We then determined
the research level of each paper (ie, whether paper is
more basic or clinical), from clinical research (RL=1.0)
to basic research (RL=4.0). This was based on the paper’s
title words according to previously described methods.17
However, a minority of papers without a title word in
either of the two lists (of clinical and basic words) could
not be so classified.

Table 1 The sex determination of cancer researchers at country level (numbers of individual researchers), 2009–2020, for
countries with at least 70 individuals
Country

M

F

U

F%

Country

M

F

U

F%

Mauritius

19

23

28

Tunisia

1833

2125

1157

54.8

Rwanda

120

63

41

34.4

53.7

Libya

115

60

68

34.3

Algeria

391

445

Madagascar

42

38

335

53.2

Uganda

351

172

97

32.9

67

47.5

Tanzania

245

119

156

32.7

South Africa

2066

Botswana

71

1714

1336

45.3

Burkina Faso

121

56

81

31.6

56

59

44.1

Togo

48

18

99

27.3

Egypt
Africa

10 243

7117

2459

41.0

Ghana

530

192

99

26.6

23 019

15 157

10 109

39.7

Cameroon

383

132

170

25.6

Mozambique

58

38

36

39.6

Sudan

334

107

112

24.3

Morocco

1947

1271

1163

39.5

Nigeria

1995

635

1125

24.1

Zimbabwe

87

56

83

39.2

Senegal

316

92

285

22.5

Zambia

74

47

76

38.8

Niger

42

8

20

16.0

Gabon

41

25

46

37.9

Mali

119

22

105

15.6

Malawi

164

98

108

37.4

Ethiopia

513

48

370

8.6

Kenya

551

298

185

35.1

Country names in bold type are North African countries.
F%, per cent of sexed names that are female; F, females; M, males; U, unknown.
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creating datasets and having these manually coded
by clinical experts as to their relevance to the cancer
research. This process gave a precision (or specificity), p,
of 0.95 and a recall (or sensitivity), r, of 0.98, which are
considered very high.
Papers were retained for analysis if they contained in
their address 1 (or more) of the 54 African countries.
(The WoS has included all the author addresses on
papers since about 1973.) Their bibliographic details
were downloaded file and converted into an MS Excel
spreadsheet with a macro (programme) written by Philip
Roe of Evaluametrics. A further macro identified the
fractional count of each country for each paper. For
example, a paper with two Egyptian and three Nigerian addresses would be categorised as EG=0.4, NG=0.6.
For each African country, we analysed the numbers of
published research papers for each year from 2009 to
2020 and calculated the average annual percentage
growth rate (AAPG). We compared fractional country
outputs during the last 5 years (2016–2020) with their
wealth as measured by their gross national product in
2015 and multiplied by the percentage of their total
disease burden in 2015 that was attributable to cancer.
This timing provided an up-to-date view of African cancer
research, and the interval between wealth measurement
and research output allowed for the time needed to do
research and publish the results.
In order to determine what percentage of each country’s biomedical research output was in the field of cancer,
we then applied a second filter to the WoS. This was
designed to identify such papers by means of words and
contractions in their addresses, for example AstraZeneca,

BMJ Global Health

Figure 2 Research output domains in Africa. WoS, Web of
Science.

The impact or influence of African countries’ cancer research
There are several ways in which the research outputs of a
country’s scientists can be evaluated. One simple measure
is the percentage of its papers that are classed as reviews,
which are usually written by invitation from journal
editors.17 A second is the relative importance of the journals in which the papers are published, measured as the
average number of citations. However, because over half
of these African papers are multinational, their journal
impact factors (JIF) are likely to be increased over those
of domestic papers, which give a better indication of a
country’s capability. We have, therefore, calculated the
mean JIF for both all papers and domestic ones.
The third measure is the number of citations. We calculated this for a 5-year window, beginning in the publication year, for papers from 2009 to 2016, from the annual
citation counts for each paper that we downloaded from
the WoS. This window was used as a compromise between
the need for immediacy (ie, citations to recent papers)
and stability (ie, inclusion of the peak year for citations,
usually the second or third year after publication). This
count was designated actual citation impact and was
also determined for all of a country’s papers, and for its
domestic ones. Finally, we determined how many of each
country’s papers received enough 5-year citations (37 or
more) to place it in the top 5% of African cancer papers
for these 8 years. This percentage was normalised to 100

Figure 3 Distribution of country research by initiator. CM,
Cameroon; DZ, Algeria; EG, Egypt; ET, Ethiopia; GH, Ghana;
KE, Kenya; MA, Morocco; NG, Nigeria; SD, Sudan; SSA,
sub-Saharan African; TN, Tunisia; TZ, Tanzania; UG, Uganda;
ZA, South Africa.

4

The sources of financial support for the research
Since 2009, the WoS has included the full acknowledgement text as a searchable field, and has also listed
the acknowledged funders of each paper in a separate
column. We listed all of the funders in this column for
five groups of countries and ranked them in descending
order of numbers of acknowledgements:
► Five North African countries (Algeria, Egypt, Libya,
Morocco, Tunisia).
► Twenty Francophone sub-Saharan countries.
► Five Lusophone (Portuguese-
speaking) countries
(Angola, Cabo Verde, Guinea-Bissau, Mozambique,
São Tomé and Príncipe).
► Eighteen Anglophone countries.
► South Africa.
We needed to combine the many different name variants as they were not standardised.
Because so many of the papers were coauthored with
countries in the Organization for Economic Coöperation and Development, much of the funding came from
these countries. In particular, some acknowledgements
were to the US National Cancer Institute and others to
the National Institutes of Health without specification of
which of some 27 individual institutes and centres had
provided support.
The author position and sex (or gender) of African cancer
researchers
We used another macro to determine the country of affiliation of the first and last authors of all the papers with an
address in sub-Saharan Africa. The intention was to see
if African countries were prominent either in doing the
majority of the work on each paper (first position) or the
most senior (usually the last position). The identities of
the first and last author on each paper were taken from
the ‘authors’ column of the spreadsheet, not from the
‘addresses’ column. However, some author names were
not listed in the address column.
We also wished to see if women were able to make a
proportionate contribution to African cancer research,
and how this varied by country. From the addresses’
column, which since 2009 in the WoS has tagged authors
with their affiliations, we were able to generate lists of
the names of authors from each African country. Most
names included a given name although some just had
initials. From previous studies, we had developed an
extensive thesaurus of over 70 000 given names with their
sex, provided that this was characteristic of over 75% of
occurrences.18 However, many African given names were
not listed, and we sought their sex from the commercial website, Gender-API, which can usually reveal the
frequency of their occurrence in their database and the
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849
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and designated as the worldscale value, by analogy with
tanker shipping ratespp.
The 17 leading African countries were then ranked on
each of these 6 indicators, and an overall ranking calculated as the sum of the individual ranks.

BMJ Global Health

Country

INT

FRAC

% int'l

Country

INT

FRAC

% int'l

Egypt

11 387

7781

31.7

Mozambique

80

27.0

66.2

South Africa

3452

2206

36.1

Mauritius

61

25.4

58.4

Tunisia

1894

1505

20.5

Mali

66

25.1

62.0

Morocco

1610

1293

19.7

Congo

43

16.8

60.9

Nigeria

1486

997

32.9

Benin

39

13.1

66.4

Algeria

506

274

45.9

Guinea

19

10.2

46.2

Ethiopia

421

248

41.0

Angola

28

8.4

70.2

Kenya

578

233

59.6

Gambia

41

8.2

79.9

Ghana

452

213

52.9

Namibia

34

7.2

78.8

Cameroon

364

177

51.4

Central African Republic

15

6.4

57.6

Uganda

427

162

62.2

Eritrea

12

6.2

48.1

Sudan

314

153

51.3

Mauritania

8

5.5

31.2

Tanzania

306

125

59.2

Liberia

13

4.0

69.3

Senegal

200

114

42.9

Sierra Leone

12

3.6

70.3

Malawi

206

75.6

63.3

Burundi

11

3.4

69.4

Libya

188

66.6

64.6

Somalia

6

3.4

43.9

Côte D'Ivoire

113

62.0

45.2

Swaziland

8

2.0

74.5

Zimbabwe

130

54.4

58.1

Cape Verde

5

1.7

66.7

Zambia

121

48.4

60.0

Chad

5

1.3

73.4

Burkina Faso

103

46.7

54.6

Lesotho

2

1.0

49.4

Botswana

120

44.6

62.8

Djibouti

2

0.45

77.5

Rwanda

103

34.2

66.8

Comoros

2

0.34

82.9

Togo

54

33.8

37.3

Seychelles

5

0.28

94.5

Madagascar

70

32.7

53.3

Guinea-Bissau

1

0.14

85.7

Democratic Republic of
the Congo

66

31.1

52.9

South Sudan

1

0.05

94.7

North African countries shown in bold.
FR, fractional counts; INT, integer counts; % int'l, percentage with international contribution.

percentages of each sex. We were able to identify sex of
79% of the people by their names, including some with
only initials if these matched those of names with the
same surnames, country and given names without ambiguity. (For example, we assumed that Abanda, F. H. from
Cameroon was male, because there was also a paper by
Abanda, Fonbeyin Henry, who is male.)

RESULTS
Cancer research outputs across Africa and in individual
countries
We found 23 679 cancer research papers over the 12-year
period (2009–2020) that contained an address from 1
or more African countries. On average, cancer research
accounted for 7.9% of all African biomedical research
outputs (figure 2); it increased from 6.5% in 2009–2010
to 8.6% in 2019–2020. For comparison, African research
in infectious diseases is plotted on the same scale. In
2009–2011, its volume was 5.1 times than that of cancer
research, but in 2018–2020 the ratio was only 3.2.
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849

On a fractional count basis, the contribution from the
African countries was 16 201 papers and the contribution
from non-African ones was 7478 papers, or 31.6%. The 5
North African countries contributed 10 920 papers (67%)
of the total on a fractional count basis. Of this total, Egypt
published the most (n=7781; 48% of all African output).
The 49 SSA countries together published just 5281
papers, of which South Africa’s contribution was 2206
(42% of the SSA total, 14% of all Africa) and Nigeria’s
contribution was 997 (19% of the SSA total, 6% of all
Africa).
The total number of papers increased rapidly with time,
with an AAPG rate of 15%, much higher than that of the
world cancer research output (7.8%) or that of the European Union (EU) (4.6%), but lower than that of China
(19%). (There was a jump of almost 50% between 2014
and 2015 because of the increased coverage of the WoS
of journals published in Africa and other non-traditional
regions.) Most African countries have a dynamic and
growing cancer research base with significant annual
growth rates in their national outputs, for example, the
5
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Table 2 Cancer research outputs by individual African countries (2009–2020)

BMJ Global Health

top SSA countries achieved an overall average growth
rate of 20% (range, 13% to 44%) (figure 3).
Country level outputs over this same period are shown
in table 2. A comparison of the cancer research outputs
of the highest output-
producing countries relative to
their wealth, measured by their gross domestic product
(GDP), and multiplied by their overall disease burden
as a percentage of all DALYs, is shown in figure 4. This
figure also includes a plot of cancer research output relative to the countries' health expenditure. The correlation
is fair but not as good as for European countries19 or Latin
America.20 For example, North African countries, Egypt
(EG) and Tunisia (TN), are clearly aligned in terms of
the country’s GDP and their overall outputs. In SSA, both
South Africa and Nigeria are similarly aligned, followed
by a group of countries at the same development stage
with major opportunities for expansion. The correlation
between country-level cancer research outputs expressed
as a percentage of DALYs is moderate (r2=0.70) (figure 5).
However, there are significant differences between north
and SSA countries, as well as between relative cancer
research outputs for the same burden. For example,
Egypt and Morocco (MA) published three times more
cancer research relative to their biomedical research
than Algeria (DZ).
International collaboration in African cancer research
Both national and international collaborative cancer
research is essential for the improvement of patient
outcomes and the building of research capacity. For
most countries, international collaboration, as measured by the presence of multiple countries among the
addresses on the papers, was very high and for some,
such as Uganda and Kenya, internationally coauthored
papers were more than six times as numerous as purely
national ones. Some international contributions were
from other African countries, but mostly they came from
Asia, Western Europe and North America. These varied
between African countries (see online supplemental
6

Figure 5 Comparison of research output versus disability
adjusted life years. BW, Botswana; CM, Cameroon; DALYs,
disability-adjusted life years; CI, Cote d'Iviore; DZ, Algeria;
EG, Egypt; ET, Ethiopia; GH, Ghana; KE, Kenya; LY, Libya;
MG, Madagascar; MU, Mauritius; MW, Malawi; NG, Nigeria;
SD, Sudan; TN, Tunisia; TZ, Tanzania; UG, Uganda; ZA,
South Africa; ZM, Zambia.

e-Figure 1). For example, two of the Francophone North
African countries (Morocco, MA; Tunisia, TN) collaborated very little internationally, although they retained
links with France, as did Algeria (DZ). Egypt (EG) collaborated mainly with Saudi Arabia, as did Sudan (SD). Nigeria’s preferred partner was Malaysia, reflecting significant
diversity in international cancer research collaboration.
To understand international collaboration in greater
depth, we analysed the affiliations of the first and last
authors of the international papers from the SSA countries (n=5303) (figure 6A). This figure shows that authors
based in SSA countries were more likely to be first
authors on these papers (42%) than last authors (30%).
Of the last authors from SSA (n=1802) much the largest
share (n=751, 42%) were based in South Africa. The last
author position was dominated by authors from the USA
(1347 papers, 25%). Western Europeans were also more
likely to be last than first authors. The leading countries
were the UK (413 papers, 7.8%), Germany (281, 5.3%)
and France (248, 4.7%). However, there were very few
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849
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Figure 4 Research output versus country’s gross domestic
product. CM, Cameroon; DALYs, disability-adjusted life
years; DZ, Algeria; EG, Egypt; ET, Ethiopia; GDP, gross
domestic product; GH, Ghana; KE, Kenya; MA, Morocco;
NG, Nigeria; SD, Sudan; TN, Tunisia; TZ, Tanzania; UG,
Uganda; ZA, South Africa.
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Indicators of African cancer research influence or impact
Table 3 shows the different measures of influence or
impact for the 17 leading African countries in terms of
output. They are ranked by their positions on six different
indicators, two of which are for their purely domestic
papers (without international contributions) and four
for all their cancer research papers. Although North
African countries have high outputs, the impact of their
cancer research papers is relatively low. This is especially
true for the three Francophone countries, whose overall
rank is lower than that of the other SSA countries listed.
The research level of the papers (a measure of how
clinical or basic the research is) averaged 1.95, which
varied very little over the 12-year study period (online
supplemental e-Figure 2). However, it did vary greatly by
country both for domestic papers and for international
ones. For all the countries studied, international papers
were more basic than domestic ones (though for South
Africa, ZA, the difference is marginal).

Figure 6 Distribution of authorship by position in different
countries. BW, Botswana; CM, Cameroon; ET, Ethiopia; GH,
Ghana; KE, Kenya; MW, Malawi; NG, Nigeria; SD, Sudan;
SN, Senegal; SSA, sub-Saharan African; TZ, Tanzania; UG,
Uganda; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe.

coauthors from Central and Eastern Europe, Oceania or
Latin America.
Authorship position in African countries is more heterogenous than Western convention based on first and
last authors. However, an analysis of such positions does
provide an understanding of the nature of international
collaborations. Researchers from Botswana (BW) and

Research on different cancer anatomical sites and in different
domains
The next analysis was of the distribution of the papers
across the different anatomical sites. Figure 7 shows the
output on each of the 16 listed in table 1 as a percentage of

Table 3 Different measures of impact and/or influence of the cancer research papers from 17 leading African countries
Country

ISO2

% revs

JIF dom

JIF all

ACI dom

ACI all

WS all

Rank

South Africa

ZA

15.8

2.3

3.7

8.7

10.5

80

23

Ethiopia

ET

14.5

2.4

3.4

9.4

10.2

95

25

Uganda

UG

10.6

2.1

5.7

6.4

11.9

75

28

Cameroon

CM

11.5

1.7

3.1

8.2

12.5

137

33

Zambia

ZM

13.7

1.8

5.6

0.0

11.4

70

39

Kenya

KE

12.6

1.7

4.8

6.3

10.3

67

40

Ghana

GH

14.8

2.2

4.4

4.9

8.4

51

40

Tanzania

TZ

9.7

1.7

3.5

6.3

11.0

101

41

Egypt

EG

6.1

2.2

2.9

8.7

10.1

72

49

Sudan

SD

12.9

1.5

2.8

4.7

7.2

61

61

Zimbabwe

ZW

9.1

1.4

5.9

3.4

6.1

66

62

Nigeria

NG

10.6

1.4

3.1

4.0

5.8

21

74

Botswana

BW

9.5

1.1

4.3

0.8

9.9

0

75

Namibia

NA

8.7

4.7

0.0

7.5

0

81

Algeria

DZ

5.2

1.3

2.9

3.9

6.6

51

82

Tunisia

TN

7.3

1.5

2.3

4.2

5.6

28

82

Morocco

MA

12.8

1.3

2.3

2.2

3.1

8

83

North Africa countries: bold type; sub-Saharan African countries: roman type.
ACI, mean 5 year citation count; dom, domestic papers without international collaboration; JIF, mean journal impact factor; overall rank, sum of individual rankings for six indicators;
% revs, percentage of reviews; WS, worldscale value for top-cited 5% of papers (with ACI=37 or more).
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South Africa (ZA) both held 40% of last author positions
for their international papers, but this ratio is closer to
20% for most of the other SSA countries. Several of them
had high levels of first author positions on their international papers, notably Cameroon (CM), with 56%, and
Nigeria (NG), with 50%, but for most countries the levels
were below 40% (figure 6B).
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Figure 7 Percentages of SSA cancer research outputs on
different cancers, 2009-20, versus the percentages of the
total African cancer disease burden in 2015 (WHO data).
Diagonal line represents equivalence; dashed lines represent
output either twice or half the amount corresponding to the
burden. BLA, bladder; BLO, Blood; CER, cervical; COL,
bowel; CNS, brain; DALYs, disability-adjusted life years; KID,
kidney; LIV, Liver; LUN, Lung; MAM, breast; MOU, head &
Neck; OES, oesophageal; OVA, ovarian; PAN, pancreatic;
PRO, prostate; SKI, malignant melanoma; STO, gastric.

the total (23 679 papers) compared with the percentage of
the overall cancer disease burden for all SSA. The correlation is moderate (r2=0.61). As in high-income settings,
breast cancer (MAM) is the site-
specific cancer with
the highest research outputs. Blood cancers, including
leukaemia (BLO), are heavily researched by a factor of
two; again reflecting what is seen in high-income settings
such as Europe.19 Research outputs that are proportionally low relative to their burden across Africa are cervical
(CER), oesophageal (OES) and prostate (PRO) cancer.
Figure 8 shows the distribution of SSA research outputs
by cancer research domain, compared with the distributions in Europe and in Latin America.19 These distributions are similar, although Africa did relatively more work
on basic discovery cancer science and genetics (GENE)
and screening (SCRE) than Europe, but less on the three
major treatment modalities (systemic therapy (DRUG),
surgery (SURG) and radiotherapy (RADI). Proportionally, very little research is carried out on palliative care
(PALL) or quality of life (QUAL), a common finding in
most countries around the world.
Paediatric cancer research in Africa accounted for 388
papers, or only 1.6% of the total. This compares with the
much higher burden of cancer on African children, which
in 2015 was 15% of total cancer DALYs in the five North
African countries and 17% in SSA. (These ratios are much
higher than those of 1.5% in North America and 1.0%
8

in Western Europe.) African paediatric cancer research
output more than doubled from 20 papers per year in
2009–2014 to 44.5 in 2015–2020, but as a percentage of
the total it declined from 2.02% in 2009–2010 to 1.47%
in 2019–2020. Its volume was clearly disproportionately
small compared with the disease burden of cancer on
African children. Such research as there was focused on
eye cancers (retinoblastomas), with more than a quarter
(n=97) of the papers, followed by leukaemia and cancers
of the peripheral nervous system (55 papers each).
We further analysed the site-
specific and research-
domain focus by individual country (online supplemental e-Tables 6 and 7). This shows a complex mosaic of
strengths and opportunities for expansion of research at
country level. For example, while overall research outputs
across all African countries on cervical cancer may be
low, the relative commitments of some countries, for
example, Nigeria, Ethiopia, Kenya, Ghana, Cameroon,
Uganda and Tanzania are high (online supplemental
e-Table 6). In contrast, the North African countries are
uniformly weak in their research on cervical cancer.
Sex (or gender) balance of African cancer research
There was a total of 82 118 individual contributions
from researchers with an address in Africa, and we estimated that these came from 48 285 different individuals.
Of these, we were able to determine that 23 019 were
male names, 15 157 were female names and 10 109 were
undetermined. They represented only 21% of the total,
thanks to the Gender-API website and to correspondents in three countries (Egypt, Ghana and Nigeria) who
were able to sex most of the relatively unusual names, a
few of which were misprinted in the WoS because of the
optical character recognition system that it used. Of the
names that could be sexed, almost 40% were female. This
compares with a world average of 36% in 2019, and indicates that female cancer researchers in Africa as a whole
have made progress, although this average hides considerable country-
level heterogeneity from 56% female
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849
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Figure 8 Research outputs by cancer domain. CLIN,
clinical research; DIAG, early diagnosis; DRUG, systemic
therapy; EPID, epidemiology; GENE, genetics; PALL,
palliative care; PATH -laboratory medicine; PROG,
biomarkers; QUAL, quality of life; RADI, radiotherapy; SCRE,
screening; SURG, surgery.
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The funding of African cancer research
North African countries enjoy significant overseas
support from the USA (NCI/NIH), the EU and some
major European national funders from countries such
as Germany and the UK. There are, of course, national
domestic funders and wider Middle East bodies (online
supplemental e-Table 12A). In sub-Saharan Africa, the
leading country, South Africa, is supported by not only
domestic funding but also international funders, particularly ones in the USA, the EU and the UK (online supplemental e-Table 12D). The NCI/NIH, USA the EU and
the UK’s Medical Research Council are also significant
funders of cancer research across SSA. Anglophone SSA
countries have the major share of this support, followed
by Francophone countries (online supplemental e-Table
12B–D).

DISCUSSION
Increasing intra-African cancer research
Despite its immense size, the cancer research output of
countries across Africa contribute only 1.3% to global
outputs compared with 2.9% of global GDP. This reflects
long term underinvestment in science and technology,
generally. African countries contribute only 1.1% to
world total health research and development expenditure.21 Furthermore, in 2006 in Khartoum, African
Heads of State and Government committed to raising
their national gross domestic expenditure on research
and development (GERD) to at least 1% of GDP.22 Yet,
most African countries have failed to achieve this even
before the impact of COVID-19. While there has been a
welcome increase in cancer research over the last decade,
this is unevenly distributed. Just 13 of 54 African countries were responsible for around 90% of total cancer
research, with two countries contributing two-
thirds
of the entire continent’s cancer (and NCD) research,
namely Egypt and South Africa.23 24 This critical finding
speaks to the need for each country to develop a strategic
plan to build cancer research as an integral part of their
National Cancer Control Plans.
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849

Our results show that most African countries are
heavily (inter)dependent on international collaboration to advance their national cancer research agenda
reflecting weak federal national funding for research.25 It
is already known that many African academic institutions
are not financially independent and have instead to look
to external research funders to sustain their activities.26
The heavy dependence on international collaboration
to support African cancer research is also reflected in
our results showing that privileged authorship ranking
(first or last authorship) is skewed towards non-African
authors. Our findings on both collaboration patterns and
authorship reflect significant power imbalances. Partly
this is driven by the need of Western authors to attain
specific positions on academic outputs.27 28 In contrast,
in many African country’s senior authorship positions
(first or last authorship) is contextual and depends on
the specific regional academic practices29 30 and international collaboration, gives many African researchers
greater global visibility and acceptance in high-impact
journals compared with domestic-originated research.31
Such power imbalances speak to the need for solutions to
drive intra-African cancer research collaboration, rather
than constantly relying on non-African partnerships.32
In addition, journals (national, regional and global)
need to develop better policies to ensure power equity in
publishing.33 34
Research priorities for African populations
Our findings show that cancer research priorities across
Africa broadly mirror those in high-income Western countries. There is a significant under-representation of key
cancer domains such as palliative care, implementation
science and qualitative research.19 The relative decline
in childhood cancer research is also a significant issue
that, as recent Commissions have pointed out, needs to
be addressed.35 Childhood cancer research accounts for
less than 2% of research analysed in this study yet has the
highest potential for improved outcomes and economic
impacts on the countries.36 In a continent with such a
large population who currently present with advanced
stages of cancer at diagnosis, there is a clear need to
prioritise clinical, palliative and qualitative research to
improve outcomes for cancer patients, with involvement
of civil society towards community participatory research
programmes and research advocacy.
The dominance of breast cancer research across Africa
also mirrors global trends with higher funding commitment compared with other cancer types due to high
civil society attention, political lobbying and funding.37
The under-representation of several other high-burden
cancers on the continent, such as liver, cervix and prostate cancers, reflects a narrow research agenda that is not
orientated to improving early diagnosis and cost-effective
interventions for curable cancers.38 For example, sub-
Saharan Africa has one of the highest incidences of
oesophageal cancer globally but it is woefully under-
represented in terms of research, as we have found.39
9
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cancer researchers in Mauritius (MU) to 10% in Ethiopia
(ET) and 9% in Mali (ML) (table 1). The North African
countries, notably Algeria (DZ), Tunisia (TN) and Egypt
(EG), score well, but most of the other countries in the
first column are Anglophone, and the majority in the
second column are Francophone.
We also analysed the sex distribution of authors in first
position (online supplemental e-Table 9), last position
(online supplemental e-Table 10) and sole authorship
papers (online supplemental e-Table 11). Despite the
significant distributional differences between the best and
worst performing countries, some such as South Africa
(ZA) and Mozambique (MZ) consistently performed well
in terms of their equitable gender balance in these significant author positions.
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Gender disparities in cancer research
Gender equality is a core development objective, embedded
in the sustainable development goals (goal 5), and essential for equitable research progress. Significant improvements have been made in the closure of gender gaps in
sub-Saharan Africa and at 61%, women in sub-Saharan
Africa have one of the highest labour force participation
rates in the world.43
A welcome finding from our research is that African
female representation in cancer research is higher than
that in most Western countries. However, we found marked
country-by-country differences, with some countries such as
Mali and Ethiopia having very low levels of female authorship. This suggests a lot more advocacy is needed to create
enabling environments to support and promote gender
equity in many African countries. This effort can also be
amplified by journal support and institutional policies for
gender equity in high ranking authorship and leadership
positions known to reduce discrepancies.44 Our findings
echo similar observations on the empowerment of female
scientists in Africa.45 A greater emphasis on gender inclusivity in African cancer research would also help address
some of the major gaps in the treatment of women’s
cancers across the continent.46
Concluding comments: Africanising cancer research
Even though the contribution of Africa to global cancer
research is increasing much of the funding and research
10

structures reflect a long history of colonialism.47 African
countries must be encouraged to engage in research
that improves cancer services and systems planning. The
governance and surveillance of research institutions must
point participants to research relevant to regional needs,
and reward them appropriately. This is an opportunity
for the African Union to implement its commitment to
improve cancer research investment in line with Agenda
2063, The Africa We Want. Institutions should be supported
to establish regional engagement of cancer researchers
with South–South African collaborations. There is a need
to redefine measures of research success across African
cancer research with outcome indicators that convey the
impact on communities, and improvement in capacity and
capabilities—building that reflect true national needs.
Non-African, relevant regional scientific evidence should
be promoted by journals and sponsors. International collaborators and major sponsors of research should coinvest in
cancer research capacity building across Africa perhaps by
prioritising ‘neglected countries’ through regional support
for less well-
established research units and in-
service
training models to enhance the research capabilities of the
existing continental health workforce. In a continent that
is struggling with the basic provision of cancer care, and
a paucity of adequate health surveillance systems, cancer
research outputs should underscore interdisciplinary
approaches and be geared towards region-specific research
that incorporates and accelerates health systems research
and focuses on outcomes and implementation. Existing
models of funding impact the choice of research and can
be overcome by academic institutions that are independent but obtain national direct government block grants
for research.
Five-point plan for building cancer research across Africa
1. All lower-
middle and upper-
middle income African
countries have committed to spend at least 1% of GDP
on gross domestic expenditure in research and development. Of this 1%, 10% should be allocated to cancer research and development across a wider range of
disciplines that address national and regional needs.
2. Research needs to be a key component of every national cancer control plan across Africa linked to hypothecated federal funding (see 1).
3. African academic institutions need to develop independent funding sources (federal and philanthropic)
that can allow them to drive their own research agenda and become less dependent on international cancer researchers and research funders.
4. New collaborative research models, including capacity building, to enhance international, regional and
South–South collaborations need to be developed and
implemented, supported by a pan-African cancer research repository.
5. Develop research across Africa including multilingual
collaborations that promote research in Francophone
and Lusophone countries, ensure ‘orphan’ high
Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849
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Re-
engineering the academic structure of African
cancer research institutions would help in establishing
a better culture focused on domestic priorities.40 This
involves a critical look at the funding and compensatory mechanisms for African academic faculty and
building a system that supports all aspects of research,
including personnel such as research assistants, statisticians and grant managers. Developing a cancer research
skills base for example modelled on National Cancer
Grid of India’s CREDO programme, which includes a
multisectoral stakeholder research taskforce that regularly reviews network cancer research priorities. African
adaptations of this model would also help establish a
collaborative research mindset which focuses on national
needs.41 Although similar models exist in a few countries,
there is need for pooled regional resources to integrate
local efforts. The AORTIC and organisations like the
Kenyan Society of Hematology and Oncology (KESHO)
could potentially assist in coordinating these priorities.
The faculty development program run by AORTIC in
collaboration with the Royal College of Physicians and
Surgeons of Canada and the Implementation Science
and Clinical Trials AORTIC special interest groups are
examples of helping to equip African faculty with skills
to perform better research. The notion of research as
‘a tedious and painful process’ in Africa is in part due
to a lack of adequate training of local ethics committees
and institutional review bodies, and acts as a deterrent to
many young researchers.42
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media–twitter spaces blogs, etc to amplify the effects of
this data.

Reflexivity statement
The research team has been led by SSA authors on behalf
of a wide collegium across the continent and including
collaborators in high-income countries, particularly the
USA and UK. From the outset the research design was
codeveloped with African authors leading on setting the
parameters of the analysis and the iterative policy discussions with the entire group. African authors are both in
first and last position with 14 of the 23 total authorships
from African countries. CN from Rwanda is an early
career researcher. All the bibliometric data (raw) has
been shared with all the coauthors and on publication
for every country this data will be made available through
multiple websites including AORTIC, KESHO, NCI,
USA and KCL GOG. We will also provide infographics
for patient and policy advocates for specific countries to
help build the case for the inclusion of cancer research
into national cancer control policy. The article will also
be fully open access as we have funds to support this.
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Patient and public involvement
During the design of the research questions to build
the bibliometric analysis, the lead authors utilised their
respective patient groups to frame some of the key questions. At subsequent round tables at least 4–6 patient
advocates attended, from Kenya, South Africa, Ghana
and Rwanda. One patient advocate (BK) put in substantial input to the analysis and drafting and thus is a coauthor. We will provide infographics for patient and policy
advocates for specific countries to help build the case
for the inclusion of cancer research into national cancer
control policy. The article will also be fully open access
as we have funds to support this. Dissemination of data
will also employ multimedia strategies including social

Twitter Miriam Mutebi @m_mutebi, Alex Mutombo @mutombomd and Fiona
Walter @fmw22

KEY MESSAGES
⇒ Qualitative studies dominate the literature on the state of cancer

research across continental Africa. This study provides a comprehensive, contemporary quantitative analysis on the state of cancer
research and a synthesis of gaps and proposed strategies and directions to proceed with.
⇒ This study provides high-
resolution, country-
specific data on
strengths and weaknesses of cancer research across Africa, by site,
by domain as well as sex distribution of authorship. It also provides
data with whom and how African authors collaborate internationally. This provides opportunities’ to assess and optimise existing
collaborations or perhaps build new ones
⇒ Cancer research intelligence is crucial for patient advocates and
policy-makers at a national level to build research into national
cancer control planning. It also informs global cancer research
funding organisations to support research that is led by and germane to national African priorities.

Mutebi M, et al. BMJ Global Health 2022;7:e009849. doi:10.1136/bmjgh-2022-009849

Contributors MM, VV, GL, JT and RS conceived the idea. All authors codesigned
the analytical frameworks and questions. GL, RS and MM conducted the analysis,
and all authors cowrote the text and recommendations. RS is the guarantor for this
paper.
Funding This study was funded by Wellcome Trust (Grant number:
215723/Z/19/Z).
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the
design, or conduct, or reporting, or dissemination plans of this research. Refer to
the Five-point plan for building cancer research across Africa section for further
details.
Patient consent for publication Not applicable.
Ethics approval This project was exempt for IRB approval
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request.
Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any opinions or recommendations discussed are solely those

11

BMJ Glob Health: first published as 10.1136/bmjgh-2022-009849 on 10 November 2022. Downloaded from http://gh.bmj.com/ on December 1, 2022 by guest. Protected by copyright.

burden cancers are represented on the continent and
‘funding deserts’ are minimised
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